Sareum (LON:SAR) Announces Earnings Results

Sareum (LON:SAR) announced its quarterly earnings data on Tuesday. The company reported GBX (0.90) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Sareum Stock Performance

Shares of LON:SAR traded up GBX 1 ($0.01) during trading on Thursday, reaching GBX 13 ($0.17). 976,388 shares of the stock traded hands, compared to its average volume of 420,953. The stock has a market cap of £16.23 million, a P/E ratio of -3.08 and a beta of -1.08. The stock has a 50-day moving average of GBX 17.82 and a two-hundred day moving average of GBX 23.19. Sareum has a 52-week low of GBX 10 ($0.13) and a 52-week high of GBX 52.50 ($0.68).

Insider Buying and Selling

In other Sareum news, insider Stephen Parker acquired 84,033 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average cost of GBX 12 ($0.15) per share, with a total value of £10,083.96 ($12,983.08). 5.02% of the stock is owned by company insiders.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.